Evidence map›Paper›PMID 25686902›Full record

ArticleBiomedical microdevices2015

Microfabricated infuse-withdraw micropump component for an integrated inner-ear drug-delivery platform.

Vishal Tandon, Woo Seok Kang, Abigail J Spencer, Ernest S Kim, Erin E L Pararas, Michael J McKenna, Sharon G Kujawa, Mark J Mescher, Jason Fiering, William F Sewell and 1 more

Abstract read
In one paragraph

Article in Biomedical microdevices, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Nanoparticles for the Treatment of Inner Ear Infections.Nanomaterials (Basel, Switzerland) · 2021
    Review
  6. [Development of novel drug carrier via round window membrane].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2021
    Review
  7. Review
  8. A nanoliter resolution implantable micropump for murine inner ear drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2019
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Vishal TandonCharles Stark Draper Laboratory, Cambridge, MA, 02139, England.
Woo Seok Kang
Abigail J Spencer
Ernest S Kim
Erin E L Pararas
Michael J McKenna
Sharon G Kujawa
Mark J Mescher
Jason Fiering
William F Sewell
Jeffrey T Borenstein
Draper Laboratory · USMassachusetts Eye and Ear Infirmary · USHarvard University · US

Funding

Micromechanical Device for Intracochlear Drug DeliveryR01DC006848 · NIDCD · CHARLES STARK DRAPER LABORATORY · PI BORENSTEIN, JEFFREY T. · 2006 to 2014
$6.4M
NIDCD NIH HHS R01 DC006848NIDCD NIH HHS R01DC006848
6 · The paper itself

Abstract

One of the major challenges in treatment of auditory disorders is that many therapeutic compounds are toxic when delivered systemically. Local intracochlear delivery methods are becoming critical in emerging treatments and in drug discovery. Direct infusion via cochleostomy, in particular, is attractive from a pharmacokinetics standpoint, as there is potential for the kinetics of delivery to be well-controlled. Direct infusion is compatible with a large number of drug types, including large, complex molecules such as proteins and unstable molecules such as siRNA. In addition, hair-cell regeneration therapy will likely require long-term delivery of a timed series of agents. This presents unknown risks associated with increasing the volume of fluid within the cochlea and mechanical damage caused during delivery. There are three key requirements for an intracochlear drug delivery system: (1) a high degree of miniaturization (2) a method for pumping precise and small volumes of fluid into the cochlea in a highly controlled manner, and (3) a method for removing excess fluid from the limited cochlear fluid space. To that end, our group is developing a head-mounted microfluidics-based system for long-term intracochlear drug delivery. We utilize guinea pig animal models for development and demonstration of the device. Central to the system is an infuse-withdraw micropump component that, unlike previous micropump-based systems, has fully integrated drug and fluid storage compartments. Here we characterize the infuse-withdraw capabilities of our micropump, and show experimental results that demonstrate direct drug infusion via cochleostomy in animal models. We utilized DNQX, a glutamate receptor antagonist that suppresses CAPs, as a test drug. We monitored the frequency-dependent changes in auditory nerve CAPs during drug infusion, and observed CAP suppression consistent with the expected drug transport path based on the geometry and tonotopic organization of the cochlea.

Indexed as

CochleaInfusion PumpsAnimalsDrug Administration RoutesDrug Delivery SystemsEquipment DesignGuinea PigsMaleMicrofluidicsMicrotechnologyMiniaturizationQuinoxalinesFG 9041Quinoxalines

Identifiers

PMID25686902
PMCPMC12134881
OpenAlexW2053424398

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.